**Recent publications**

Following you find a brief abstract of a scientific publication concerning LEUKOCARE’s technologies. Please find the full text article at the given reference.


**Fas/Fasl interaction: a novel immune therapy approach with immobilized biologicals.**

SCHOLZ M, CINATL J.

Institute of Medical Virology, Johann Wolfgang Goethe University, Frankfurt am Main, Germany.
m.scholz@em.uni-frankfurt.de

Systemically applied agents to modulate the Fas/Fasl system, e.g., by stimulation of Fas on activated leukocytes or tumor cells failed as strategies in immune therapy due to severe toxic effects in the host. Recently, a novel strategy has been developed by using immobilized immune active biologicals in a medical device that may allow immune management without expensive systemic therapy. This review reports on the potential role of Fas/Fasl in immune therapy and summarizes current experimental and clinical data with the leukocyte inhibition module (LIM), an immobilized anti-Fas antibody containing device yet used in extracorporeal blood circulation. This proof of principle may stimulate the development of other devices based on the regulation of Fas/Fasl or other targets relevant for immune disorders. Copyright (c) 2004 Wiley Periodicals, Inc.